IRIS UniCatt

Criscuolo, Marianna
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.056
EU - Europa 2.566
AS - Asia 1.231
SA - Sud America 267
AF - Africa 28
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 6
Totale 7.164
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.023
DE - Germania 933
SE - Svezia 507
CN - Cina 474
SG - Singapore 412
IT - Italia 237
BR - Brasile 226
UA - Ucraina 184
FR - Francia 150
IE - Irlanda 126
PL - Polonia 115
IN - India 110
ID - Indonesia 83
FI - Finlandia 64
GB - Regno Unito 61
RU - Federazione Russa 59
TR - Turchia 27
NL - Olanda 25
BE - Belgio 18
KR - Corea 18
CA - Canada 16
JP - Giappone 16
HK - Hong Kong 15
NO - Norvegia 15
AT - Austria 14
VN - Vietnam 14
AR - Argentina 12
MX - Messico 12
CI - Costa d'Avorio 11
ES - Italia 11
AU - Australia 10
CL - Cile 9
CZ - Repubblica Ceca 8
IR - Iran 8
CO - Colombia 7
TH - Thailandia 7
ZA - Sudafrica 7
IL - Israele 6
LT - Lituania 6
PK - Pakistan 6
AE - Emirati Arabi Uniti 5
CH - Svizzera 5
GR - Grecia 5
IQ - Iraq 5
EC - Ecuador 4
RO - Romania 4
BD - Bangladesh 3
BG - Bulgaria 3
DO - Repubblica Dominicana 3
HU - Ungheria 3
JO - Giordania 3
LV - Lettonia 3
MY - Malesia 3
VE - Venezuela 3
BO - Bolivia 2
BW - Botswana 2
EG - Egitto 2
EU - Europa 2
HR - Croazia 2
KZ - Kazakistan 2
LA - Repubblica Popolare Democratica del Laos 2
MD - Moldavia 2
NP - Nepal 2
PA - Panama 2
PH - Filippine 2
PS - Palestinian Territory 2
PY - Paraguay 2
SK - Slovacchia (Repubblica Slovacca) 2
TN - Tunisia 2
XK - ???statistics.table.value.countryCode.XK??? 2
A1 - Anonimo 1
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
AZ - Azerbaigian 1
DK - Danimarca 1
DZ - Algeria 1
GE - Georgia 1
IS - Islanda 1
KE - Kenya 1
KG - Kirghizistan 1
LK - Sri Lanka 1
MA - Marocco 1
PE - Perù 1
PT - Portogallo 1
RS - Serbia 1
SO - Somalia 1
UY - Uruguay 1
UZ - Uzbekistan 1
Totale 7.164
Salva come PNG Salva come JPEG
Città #
Chandler 559
Singapore 270
Ashburn 187
Jacksonville 138
Dublin 120
San Mateo 112
Ann Arbor 109
Chicago 109
Warsaw 109
Dearborn 96
Woodbridge 94
Houston 93
Nanjing 93
Jakarta 81
Wilmington 81
Los Angeles 76
New York 70
Munich 58
Fairfield 56
Milan 51
Boston 47
Bremen 44
Moscow 44
Hyderabad 43
Nürnberg 40
Cattolica 38
Seattle 38
Redwood City 37
Nanchang 36
Princeton 34
Lawrence 33
Beijing 27
São Paulo 27
Buffalo 26
Hefei 26
Salt Lake City 26
Frankfurt am Main 24
Rome 24
Hangzhou 23
Marseille 23
Shanghai 21
The Dalles 21
Leawood 20
Shenyang 20
Mountain View 19
Brussels 18
Cambridge 18
Kunming 17
Seoul 17
Chatsworth 16
Redmond 16
Auburn Hills 14
Augusta 14
Hong Kong 14
London 14
Falls Church 13
Izmir 13
Pune 13
Tampa 13
Zhengzhou 13
Guangzhou 12
Hebei 12
Abidjan 11
Boardman 11
Changsha 11
Elk Grove Village 11
Norwalk 11
Nuremberg 11
Tianjin 11
Jiaxing 10
Lappeenranta 10
Hanoi 9
Helsinki 9
Jinan 9
University Park 9
Washington 9
Brooklyn 8
Philadelphia 8
Santa Clara 8
Simi Valley 8
Belo Horizonte 7
Falkenstein 7
Halden 7
Cape Town 6
Düsseldorf 6
Edinburgh 6
Enterprise 6
Mexico City 6
Portsmouth 6
Tokyo 6
Athens 5
Bolzano 5
Fremont 5
Lanzhou 5
Las Vegas 5
Miami 5
Paris 5
Rio de Janeiro 5
San Francisco 5
Sterling 5
Totale 3.857
Salva come PNG Salva come JPEG
Nome #
5-azacytidine in chronic myelomonocytic leukemia: case report and review of literature 372
Fanconi anemia gene variants in therapy-related myeloid neoplasms 275
PTEN/PI3K/AKT PATHWAY DYSREGULATION IN MYELODYSPLASTIC GRANULOCYTES 193
MTHFR polymorphysms in myelodysplastic syndromes and therapy-related myeloid neoplasms 150
Characteristics and outcome of therapy-related myeloid neoplasms: Report from the italian network on secondary leukemias. 147
Why methylation is not a marker predictive of response to hypomethylating agents 144
Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases 143
Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas. 141
Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases 139
SETBP1 mutations in 106 patients with therapy-related myeloid neoplasms. 139
Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database 137
in Higher-Risk Myelodysplastic Syndromes and Low Blast Count Acute Myeloid Leukemia: Results of the BMT-AZA Prospective Study 137
Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia. 132
Impairment of PI3K/AKT and WNT/β-catenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes 132
Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms 128
Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma 128
Primary plasma cell leukemia followed by testicular plasmacytoma 121
Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma. 121
Epigenetic changes in therapy-related MDS/AML 118
Polymorphisms of detoxification and DNA repair enzymes in myelodyplastic syndromes 118
Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms 118
Similarities and differences between therapy-related and elderly acute myeloid leukemia 115
Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas 112
Tumor lysis syndrome: review of pathogenesis, risk factors and management of a medical emergency 112
Changes in the incidence of candidemia and related mortality in patients with hematologic malignancies in the last ten years. A SEIFEM 2015-B report 111
Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine 108
Outcome of therapy-related myeloid neoplasms treated with azacitidine 101
The BCL2L10 Leu21Arg variant and risk of therapy-related myeloid neoplasms and de novo myelodysplastic syndromes 101
Clonal evolution in therapy-related neoplasms 97
Treatment of primary plasma cell leukemia with high doses of cyclophosphamide, bortezomib, and dexamethasone followed by double autologous HSCT 97
Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia 96
Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study 91
Transcription factors implicated in late megakaryopoiesis as markers of outcome after azacitidine and allogeneic stem cell transplantation in myelodysplastic syndrome 88
SEIFEM 2017: from real life to an agreement on the use of granulocyte transfusions and colony-stimulating factors for prophylaxis and treatment of infectious complications in patients with hematologic malignant disorders 86
Impairment of PI3K/AKT and WNT/β-catenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes 85
Azacitidine in a patient with myelodysplastic syndrome: Impact of switching from a 5-day to the approved 7-day dosing schedule 84
Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia 80
High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study 77
Bloodstream infections caused by Escherichia coli in onco-haematological patients: Risk factors and mortality in an Italian prospective survey 77
Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes. 76
Extramedullary Involvement in Acute Myeloid Leukemia. A Single Center Ten Years' Experience 76
Therapy-related myeloid neoplasms: Clinical perspectives 75
Candidaemia in haematological malignancy patients from a SEIFEM study: Epidemiological patterns according to antifungal prophylaxis 74
TREATMENT OF INDOLENT AND ADVANCED SYSTEMIC MASTOCYTOSIS 72
Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations 71
Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes 70
Aggressive Light Chain Myeloma Originating a Double Peak on Serum Electrophoresis: What's Underneath? 70
A population-based study on myelodysplastic syndromes in the Lazio Region (Italy), medical miscoding and 11-year mortality follow-up: The Gruppo Romano-Laziale Mielodisplasie experience of retrospective multicentric registry 70
In vitro Effect of Eltrombopag Alone and in Combination With Azacitidine on Megakaryopoiesis in Patients With Myelodysplastic Syndrome 67
Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a “Gruppo Romano Mielodisplasie (GROM)” multicenter study 66
SEIFEM 2017: from real life to an agreement on the use of granulocyte transfusions and colony-stimulating factors for prophylaxis and treatment of infectious complications in patients with hematologic malignant disorders 66
Rapid response of nodular CD30-positive mycosis fungoides to brentuximab vedotin 65
Allogeneic Transplant for Mycosis Fungoides in Patient with Wiskott-Aldrich Syndrome 65
Risk of infectious complications in patients with chronic lymphocytic leukemia in the era of BCR inhibitors: a retrospective single institution experience 63
Invasive aspergillosis in acute myeloid leukemia: Are we making progress in reducing mortality? 62
Considerations on antimicrobial prophylaxis in patients with lymphoproliferative diseases: A SEIFEM group position paper 62
A bronchoalveolar lavage-driven antimicrobial treatment improves survival in hematologic malignancy patients with detected lung infiltrates: A prospective multicenter study of the SEIFEM group 60
The validity of the fifth and the 10th Body Mass Index percentile as weight cut-offs for anorexia nervosa in adolescence: No evidence from quantitative and network investigation of psychopathology 59
Risk of infectious complications in patients with chronic lymphocytic leukemia in the era of BCR inhibitors: a retrospective single institution experience 58
Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry 57
Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study 56
Impact of invasive aspergillosis occurring during first induction therapy on outcome of acute myeloid leukaemia (SEIFEM-12B study) 56
Disseminated geosmithia argillacea infection in a patient with ph-positive acute lymphoblastic leukemia. Case report and literature review 55
Invasive aspergillosis in acute myeloid leukemia: Are we making progress in reducing mortality? 54
Systemic mastocytosis revisited with an emphasis on skeletal manifestations 53
Isavuconazole in Hematological Patients: Results of a Real-Life Multicentre Observational Seifem Study 52
Fungaemia in haematological malignancies: SEIFEM-2015 survey 51
Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata 48
Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022 41
Clinical features and prognostic factors of Magnusiomyces (Saprochaete) infections in haematology. A multicentre study of SEIFEM/Fungiscope 39
Mastocytosis: One Word for Different Diseases 37
Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry 37
High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM Study 34
SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted 33
Bloodstream infections due to Gram-negative bacteria in patients with hematologic malignancies: updated epidemiology and risk factors for multidrug-resistant strains in an Italian perspective survey 33
A review of prophylactic regimens to prevent invasive fungal infections in hematology patients undergoing chemotherapy or stem cell transplantation 31
Second Neoplasms in Italian Patients with Hairy Cell Leukemia after Treatment with Cladribine: A Multicenter Investigation and Literature Review 30
SARS-CoV-2 Infection In Patients With Mastocytosis: An EPICOVIDEHA Report 29
In vitro effect of eltrombopag alone and in combination with azacitidine on megakaryopoiesis in patients with myelodysplastic syndrome 27
The clinical experience of compassionate use program for avapritinib: implications for drug positioning in the therapeutic scenario of systemic mastocytosis 22
Unveiling the Hidden Burden: From EPICOVIDEHA to EPIFLUEHA, Exploring the Epidemiology of Respiratory Viral Infections in Hematological Patients 22
Management of latent tuberculosis infection (LTBI) in adult patients with newly diagnosed acute leukemia: results of a survey among Italian centers belonging to SEIFEM (Sorveglianza Epidemiologica Infezioni nelle Emopatie) group 20
Revision of antifungal strategies definitions for invasive fungal infections (proven/probable/possible) in 461 patients with haematological malignancies (REDEFI-SEIFEM) 18
Antiviral prophylaxis to prevent herpes simplex virus (HSV) and varicella zoster virus (VZV) reactivation in adult patients with newly diagnosed acute leukemia: results of a survey submitted to Italian centers belonging to SEIFEM (Sorveglianza Epidemiologica Infezioni nelle Emopatie) group 17
Totale 7.250
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.034
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.034
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202057 0 0 0 0 0 0 0 0 0 0 0 57
2020/2021637 27 51 15 46 65 82 83 18 56 53 123 18
2021/2022689 64 39 8 29 51 35 13 122 37 72 94 125
2022/20231.446 185 206 122 267 77 180 50 110 157 20 52 20
2023/2024734 37 185 27 27 29 131 60 15 11 26 90 96
2024/20251.620 49 58 128 54 155 24 90 73 226 170 563 30
Totale 7.250